CRESCENT BIOPHARMA, INC. (CBIO) Cash Flow Statement
CRESCENT BIOPHARMA, INC. (CBIO) generated -$72.7M of operating cash flow over the twelve months to 2026-06-30, spent $939000 on capital expenditure and had free cash flow of -$73.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CBIOCRESCENT BIOPHARMA, INC.Follow CBIO — free
—
Price chart with a free account
- Market cap
- 476.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -4.3 | -8.2 | -29.7 | -39.2 | -57.5 | -46.5 | -34.9 | -71.5 | -72.7 | |
| Capital expenditure | 0.2 | 0.3 | 0.7 | 0.1 | 0.0 | 0.1 | 0.0 | 0.9 | -0.9 | |
| Free cash flow | -4.5 | -8.5 | -30.4 | -39.3 | -57.5 | -46.5 | -34.9 | -72.5 | -73.6 | |
| Stock-based compensation | — | — | 3.0 | 6.9 | 6.1 | 3.9 | 3.5 | 13.3 | — |
USD millions · SEC XBRL
CRESCENT BIOPHARMA, INC. — questions
- What is CRESCENT BIOPHARMA, INC.'s operating cash flow?
- -$72.7M over the twelve months to 2026-06-30.
- How much does CRESCENT BIOPHARMA, INC. spend on capital expenditure?
- $939000 over the twelve months to 2026-06-30.
- What is CRESCENT BIOPHARMA, INC.'s free cash flow?
- -$73.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from CRESCENT BIOPHARMA, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.